the triple agonist gets read properly instead of admired

A second wave of interest in retatrutide arrived and the channel handled it better than the first. The Phase 2 paper was read in full, including the tolerability tables, and the heart rate logging habit established last summer meant the room had its own small pile of data to put beside it. Low and slow held as the consensus without much argument.

• The retatrutide Phase 2 result in NEJM 2023 was discussed for its adverse event profile as much as its efficacy, which is not how it usually gets quoted.
• Eleven members had heart rate baselines from before starting, which made their reports far more useful than the enthusiasm of a year earlier.
• The glucagon arm was discussed as a mechanism with consequences rather than as a marketing feature of a molecule.
• One member stopped after four weeks on the strength of their own data and posted the whole log, which the channel considered the best outcome available.
• noct.titrate maintained the position that anybody running this without daily observations is generating no information at all.